Komodo Health
Health data company mapping 330M+ patient journeys for AI-driven analytics and research.
On the record
Checkpoint: Next primary funding round or S-1 filing that confirms or refutes the reported 94% valuation markdown
The call
The data asset behind Komodo still looks solid, but flat revenue, a stalled IPO, and a reported 94% valuation cut show the business around it losing altitude.
Komodo Health buys and sells information about patient medical visits and treatments, and built an AI tool called Marmot to help companies use that data. The company has collected records on over 330 million patient journeys over 11 years, which is hard for competitors to copy quickly. However, a much larger company called IQVIA already has 1.2 billion patient records and does the same work, so Komodo is not the only option in the market. The company's revenue has stayed flat around $150 million to $380 million for years, its value has dropped by 94 percent since 2021, and it froze hiring, all signs the business is not growing as hoped. The one thing that could change the picture is whether Marmot starts bringing in much larger customers and grows revenue past $250 million per year; if that happens, the company could be worth joining, but if revenue stays flat or the company takes a down-round in funding, the financial situation will probably stay weak.
Why
01
AI pressure: Truveta (EHR-direct data AI), generic foundation models (OpenAI, Anthropic, Google). Foundation models can't replicate licensed patient data, but Truveta builds a rival AI-on-data engine straight from EHR pipes. Could AI do the core job? Unlikely.
02
Bigger players: IQVIA (1.2B+ patient records globally). IQVIA has more records, deeper pharma relationships, and no real barrier stopping it from matching Komodo's offer feature for feature. Could a giant copy it? Yes, easily.
03
What protects it. 11 years of licensed, de-identified data relationships covering 330M+ patient journeys that a model alone can't buy or scrape.
What would change this call
Komodo closes a new primary funding round within the next year. Would show whether investors value it near, above, or far below the 94% markdown estimate.
Komodo files an S-1 or confirms IPO plans. Would show whether the stalled 2022 IPO track is back on or shelved further.
A major pharma or payer customer publicly switches to IQVIA or Truveta from Komodo. Would confirm the incumbent is actively displacing Komodo rather than just competing on paper.
Komodo files an S-1 or confirms IPO plans. Would show whether the stalled 2022 IPO track is back on or shelved further.
A major pharma or payer customer publicly switches to IQVIA or Truveta from Komodo. Would confirm the incumbent is actively displacing Komodo rather than just competing on paper.
Key numbers
- 330M+ patient journeys mapped
- Valuation implied down ~94% to $0.2B
- $200M+ ARR in FY2023, roughly flat since
Named risks
- Secondary-market trackers imply a steep unconfirmed valuation decline since the 2021 $3.3B round.
- Stalled 2022 IPO with no confirmed S-1 filing as of July 2026 despite renewed speculation.
- Active job postings fell 36.9% year-over-year in 2025, signaling hiring deceleration.
- June 2026 co-CEO and President restructuring introduces governance and continuity uncertainty.
- Revenue figures across sources conflict sharply ($168M to $380M), making financial health hard to verify.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| IQVIA | gaining on | Holds 1.2B+ global patient records vs Komodo's 330M+, no structural barrier to competing (2026-07-10) |
| Truveta | contesting | EHR-based data clustering platform competing directly in real-world-data market as of 2026-07-10 |
| HealthVerity | contesting | Competing RWD marketplace and data-linkage vendor named in 2026 vendor comparison |
| Datavant | contesting | Data linkage rival that is also a Komodo partner, per 2026 vendor comparison |
| Tempus | contesting | Oncology/precision-medicine multimodal data competitor listed in 2026 vendor comparison |
Questions people ask
- Is Komodo Health profitable?
- No public profitability figures are disclosed. Komodo, a private company, states it exceeded $200M in Annual Recurring Revenue in fiscal year 2023 (announced 2024-06-05), but has not published net income, and outside revenue estimates for 2024 range widely from $168M to $380M.
- Has Komodo Health had layoffs?
- Yes. In December 2022 Komodo Health cut about 9% of staff (roughly 78 employees) alongside a CFO departure and a $200M structured equity raise led by Coatue and Dragoneer, per TechCrunch reporting dated 2022-12-13.
- Who is Komodo Health's biggest competitor?
- IQVIA is Komodo Health's largest rival, holding 1.2B+ global patient records versus Komodo's 330M+ US/Canada patient journeys (as of 2025-08-20), with no structural barrier stopping IQVIA from competing directly in the same real-world-data market.
- Could AI replace Komodo Health?
- Unlikely to be replaced by generic AI models. Komodo's own healthcare-native AI, Marmot, launched August 20, 2025, runs on its proprietary 330M+ patient-journey dataset built over 11 years, a data relationship generic foundation models like OpenAI or Anthropic cannot replicate.
- Is Komodo Health going public soon?
- Not confirmed. Komodo was rumored for a 2022 IPO that never materialized, and appeared on a CB Insights 2026 IPO-pipeline watchlist (2026-01-16), but no S-1 filing had been made as of July 2026.
- What is Komodo Health's revenue?
- Komodo states it exceeded $200M in Annual Recurring Revenue in fiscal year 2023, announced 2024-06-05. Third-party estimates for later years vary widely, from $168M to $380M, so figures should be treated as inconsistent estimates rather than confirmed financials.
Timeline
- 2026-06-25Expanded Alnylam Pharmaceuticals partnership to scale Marmot AI across enterprise functions
- 2026-06-16Leadership restructuring: Web Sun named co-CEO with Arif Nathoo, Miles Ennis named President
- 2025-12-18Komodo Health launches availability on AWS Marketplace
- 2025-08-20Komodo launches Marmot, proprietary healthcare-native generative-AI engine
- 2025-05-02Komodo partners with Nasdaq to sell Healthcare Map data to financial services firms
- 2024-06-05Komodo states it exceeded $200M ARR in fiscal year 2023 (announced with CFO appointment)
- 2022-12-13Komodo cuts ~9% of staff (~78 employees) and CFO departs amid $200M structured equity raise
- 2022-11$200M structured equity infusion led by Coatue Management and Dragoneer Investment Group
- 2021-03Series E: $220M raised led by Tiger Global and Casdin Capital, valuation hits $3.3B
- 2020-01Series C funding round of $50M closed
Revision history
21 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Komodo Health Appoints Vikas Mehta as CFO; Names Sarah Shin as CPO (2024-11-19)
- Komodo Health Introduces Marmot | Marmot AI Platform (2025-08-20)
- Komodo Health (2026-04-29)
- Report: Komodo Health Business Breakdown & Founding Story
- Komodo Health banks $200M as it lays out restructuring plans (2022-12-13)
- Company Profile (2026-06-30)
- Komodo Health, once tipped for a looming IPO, has cut staff as CFO departs (2022-12-13)
- Komodo Health Number of Employees 2026 (2026-06-29)
- Komodo Health (2025-08-19)
- Komodo Health Partners With Nasdaq (2025-05-02)
- Komodo Expands Strategic Partnership With Alnylam (2026-06-25)
- Komodo Health Announces Availability in AWS Marketplace (2025-12-18)